2. League table ‐ Network meta‐analysis.
| IPSS scores ‐ short term (mean difference in IPSS scores and 95% CI) | |||||||
| TURP | PUL | PAE | REZUM | TUMT | iTIND | ||
| TURP | 1.47 (‐4.00,6.93) | 1.55 (‐1.23,4.33) | 3.60 (‐4.25,11.46) | 3.98 (0.85,7.10) | 7.50 (‐0.68,15.69) | ||
| PUL | ‐1.47 (‐6.93,4.00) | 0.09 (‐5.85,6.02) | 2.14 (‐6.56,10.84) | 2.51 (‐3.13,8.15) | 6.04 (‐2.96,15.03) | ||
| PAE | ‐1.55 (‐4.33,1.23) | ‐0.09 (‐6.02,5.85) | 2.05 (‐6.02,10.13) | 2.43 (‐1.50,6.35) | 5.95 (‐2.44,14.34) | ||
| REZUM | ‐3.60 (‐11.46,4.25) | ‐2.14 (‐10.84,6.56) | ‐2.05 (‐10.13,6.02) | 0.37 (‐7.17,7.91) | 3.90 (‐6.05,13.84) | ||
| TUMT | ‐3.98 (‐7.10,‐0.85) | ‐2.51 (‐8.15,3.13) | ‐2.43 (‐6.35,1.50) | ‐0.37 (‐7.91,7.17) | 3.53 (‐4.35,11.41) | ||
| iTIND | ‐7.50 (‐15.69,0.68) | ‐6.04 (‐15.03,2.96) | ‐5.95 (‐14.34,2.44) | ‐3.90 (‐13.84,6.05) | ‐3.53 (‐11.41,4.35) | ||
| IPSS QOL scores ‐ short term (mean difference in IPSS scores and 95% CI) | |||||||
| TURP | PUL | PAE | REZUM | TUMT | iTIND | ||
| TURP | 0.06 (‐1.17,1.30) | 0.09 (‐0.57,0.75) | 0.37 (‐1.45,2.20) | 0.65 (‐0.48,1.78) | 0.87 (‐1.04,2.79) | ||
| PUL | ‐0.06 (‐1.30,1.17) | 0.03 (‐1.29,1.35) | 0.31 (‐1.59,2.21) | 0.59 (‐0.81,1.99) | 0.81 (‐1.18,2.80) | ||
| PAE | ‐0.09 (‐0.75,0.57) | ‐0.03 (‐1.35,1.29) | 0.28 (‐1.55,2.12) | 0.56 (‐0.63,1.76) | 0.78 (‐1.14,2.70) | ||
| REZUM | ‐0.37 (‐2.20,1.45) | ‐0.31 (‐2.21,1.59) | ‐0.28 (‐2.12,1.55) | 0.28 (‐1.46,2.02) | 0.50 (‐1.67,2.67) | ||
| TUMT | ‐0.65 (‐1.78,0.48) | ‐0.59 (‐1.99,0.81) | ‐0.56 (‐1.76,0.63) | ‐0.28 (‐2.02,1.46) | 0.22 (‐1.62,2.06) | ||
| iTIND | ‐0.87 (‐2.79,1.04) | ‐0.81 (‐2.80,1.18) | ‐0.78 (‐2.70,1.14) | ‐0.50 (‐2.67,1.67) | ‐0.22 (‐2.06,1.62) | ||
| Sham | ‐1.57 (‐2.65,‐0.50) | ‐1.51 (‐2.71,‐0.31) | ‐1.48 (‐2.57,‐0.40) | ‐1.20 (‐2.68,0.28) | ‐0.92 (‐1.85,0.01) | ‐0.70 (‐2.28,0.88) | |
| Major adverse events ‐ risk ratio and 95% CI | |||||||
| TURP | TUMT | PUL | CRFWVT | TIND | PAE | ||
| TURP | 0.20 (0.09,0.43) | 0.30 (0.04,2.22) | 0.37 (0.01,18.62) | 0.52 (0.01,24.46) | 0.65 (0.25,1.68) | ||
| TUMT | 4.95 (2.32,10.57) | 1.50 (0.18,12.64) | 1.85 (0.03,99.13) | 2.57 (0.05,130.34) | 3.23 (0.96,10.88) | ||
| PUL | 3.29 (0.45,24.04) | 0.66 (0.08,5.59) | 1.23 (0.03,58.48) | 1.71 (0.04,76.76) | 2.14 (0.26,17.85) | ||
| CRFWVT | 2.68 (0.05,133.78) | 0.54 (0.01,29.08) | 0.81 (0.02,38.83) | 1.39 (0.02,94.69) | 1.75 (0.04,85.57) | ||
| TIND | 1.93 (0.04,90.82) | 0.39 (0.01,19.76) | 0.59 (0.01,26.34) | 0.72 (0.01,48.95) | 1.26 (0.03,58.08) | ||
| PAE | 1.53 (0.59,3.96) | 0.31 (0.09,1.05) | 0.47 (0.06,3.88) | 0.57 (0.01,28.02) | 0.80 (0.02,36.80) | ||
| Retreatment ‐ long term ‐ risk ratio and 95% CI | |||||||
| TURP | PUL | PAE | TUMT | ||||
| TURP | 2.39 (0.51,11.10) | 4.39 (1.25,15.44) | 9.71 (2.35,40.13) | ||||
| PUL | 0.42 (0.09,1.95) | 1.84 (0.25,13.41) | 4.07 (0.50,32.97) | ||||
| PAE | 0.23 (0.06,0.80) | 0.54 (0.07,3.96) | 2.21 (0.33,14.72) | ||||
| TUMT | 0.10 (0.02,0.43) | 0.25 (0.03,1.99) | 0.45 (0.07,3.01) | ||||
| Erectile function ‐ short term (mean difference in IIEF scores and 95% CI) | |||||||
| TURP | CRFWVT | TIND | PUL | PAE | |||
| TURP | 6.49 (‐8.13,21.12) | 5.19 (‐9.36,19.74) | 3.00 (‐5.45,11.44) | ‐0.03 (‐6.38,6.32) | |||
| CRFWVT | ‐6.49 (‐21.12,8.13) | ‐1.30 (‐13.33,10.73) | ‐3.50 (‐15.44,8.45) | ‐6.52 (‐22.47,9.42) | |||
| TIND | ‐5.19 (‐19.74,9.36) | 1.30 (‐10.73,13.33) | ‐2.20 (‐14.05,9.66) | ‐5.22 (‐21.10,10.65) | |||
| PUL | ‐3.00 (‐11.44,5.45) | 3.50 (‐8.45,15.44) | 2.20 (‐9.66,14.05) | ‐3.03 (‐13.59,7.54) | |||
| PAE | 0.03 (‐6.32,6.38) | 6.52 (‐9.42,22.47) | 5.22 (‐10.65,21.10) | 3.03 (‐7.54,13.59) | |||
| Ejaculatory function ‐ risk ratio and 95% CI | |||||||
| TURP | PUL | PAE | TUMT | ||||
| TURP | 0.05 (0.00,1.06) | 0.35 (0.13,0.92) | 0.34 (0.17,0.68) | ||||
| PUL | 18.75 (0.94,372.21) | 6.61 (0.29,152.77) | 6.35 (0.29,136.77) | ||||
| PAE | 2.83 (1.08,7.43) | 0.15 (0.01,3.49) | 0.96 (0.31,2.98) | ||||
| TUMT | 2.95 (1.46,5.98) | 0.16 (0.01,3.39) | 1.04 (0.34,3.23) | ||||
| Minor adverse events ‐ risk ratio and 95% CI | |||||||
| TURP | TUMT | CRFWVT | TIND | PAE | Rank (SUCRA) | ||
| TURP | 1.43 (0.74,2.75) | 1.78 (0.51,6.21) | 3.35 (0.74,15.26) | 1.06 (0.57,1.99) | 2.4 (72.4%) | ||
| TUMT | 0.70 (0.36,1.35) | 1.24 (0.40,3.91) | 2.35 (0.56,9.81) | 0.74 (0.35,1.60) | 4.0 (39.6%) | ||
| CRFWVT | 0.56 (0.16,1.96) | 0.80 (0.26,2.53) | 1.88 (0.36,9.79) | 0.60 (0.17,2.13) | 4.3 (32.0%) | ||
| TIND | 0.30 (0.07,1.36) | 0.43 (0.10,1.78) | 0.53 (0.10,2.76) | 0.32 (0.07,1.47) | 5.5 (10.6%) | ||
| PAE | 0.94 (0.50,1.76) | 1.34 (0.62,2.89) | 1.67 (0.47,5.95) | 3.15 (0.68,14.57) | 2.7 (66.2%) | ||
| Acute urinary retention ‐ risk ratio and 95% CI | |||||||
| TURP | TUMT | PUL | CRFWVT | TIND | PAE | Rank (SUCRA) | |
| TURP | 2.93 (1.19,7.22) | 1.09 (0.12,10.03) | 2.02 (0.07,55.79) | 2.73 (0.10,73.42) | 1.82 (0.75,4.41) | 3.1 (65.5%) | |
| TUMT | 0.34 (0.14,0.84) | 0.37 (0.04,3.43) | 0.69 (0.03,17.12) | 0.93 (0.04,22.51) | 0.62 (0.17,2.26) | 5.7 (22.1%) | |
| PUL | 0.92 (0.10,8.49) | 2.69 (0.29,24.92) | 1.86 (0.04,78.93) | 2.51 (0.06,104.22) | 1.68 (0.15,18.46) | 3.6 (56.8%) | |
| CRFWVT | 0.50 (0.02,13.71) | 1.45 (0.06,36.08) | 0.54 (0.01,22.91) | 1.35 (0.02,96.96) | 0.90 (0.03,28.27) | 4.5 (42.0%) | |
| TIND | 0.37 (0.01,9.83) | 1.07 (0.04,25.85) | 0.40 (0.01,16.48) | 0.74 (0.01,52.83) | 0.67 (0.02,20.29) | 5.0 (33.9%) | |
| PAE | 0.55 (0.23,1.33) | 1.61 (0.44,5.85) | 0.60 (0.05,6.58) | 1.11 (0.04,34.71) | 1.50 (0.05,45.73) | 4.7 (38.8%) | |
Each cell represents the effect of the intervention in the column versus the intervention in the row. CI: confidence interval; CRFWVT: convective radiofrequency water vapor therapy; IPSS: International Prostate Symptom Score; PAE: prostatic arterial embolization; PUL: prostatic urethral lift; QoL: quality of life; SUCRA: surface under the cumulative ranking curve; TIND: temporary implantable nitinol device; TUMT: transurethral microwave thermotherapy; TURP: transurethral resection of the prostate.